Secondary Prevention With Compound Danshen Dripping Pills Of Coronary Artery Disease In Hemodialysis Patients:a Retrospective Study

ObjectiveTo observe the effect and safety of Compound Danshen Dripping Pills on coronary artery disease outcomes in maintenance hemodialysis patients and analyze the influencing factors of survival in maintenance hemodialysis patients with coronary artery disease.MethodsAccording to inclusion and exclusion criteria,57maintenance hemodialysis patients with coronary artery disease from Hemodialysis Center of Guangdong Provincial Hospital of Chinese Medicine were enrolled in this retrospective cohort study in the period from January1,2010to December31,2012. According to medication use,57patients were divided into Compound Danshen Dripping Pills group(n=27) and antiplatelet drugs group(n=30)consist of Aspirin and Clopidogrel. Baseline clinical data、all endpoint events and adverse events were recorded and compared. The influencing factors of all-cause mortality was analyzed by Cox proportional-hazards regression.ResultsThe incidence of all endpoint events in two groups had no significant difference (P>0.05)by Chi-square test. Also the Kaplan-meier survival curves of the two groups had no significant difference (P=0.655) by long-rank test. The diabetes and serum albumin adjusted Cox regression model showed that survival from all-cause mortality was also no significant difference of the two groups. The major bleeding events in Compound Danshen Dripping Pills group was11.1%VS26.7%(antiplatelet drugs group). The Cox regression model showed that the influencing factors of survival of57patients were diabetes,β-blockers, pre-dialysis systolic blood pressure and calcium channel blockers, relative risk were3.816、8.672、0.966、0.316and P values were0.015、 0.008、0.014、0.061, respectively.ConclusionCompared with antiplatelet drugs, Compound Danshen Dripping Pills didn’t reduce endpoint events in maintenance hemodialysis patients with coronary artery disease, they possibly had considerable effect. It was difficult to prove the risk of major bleeding events had significantly difference between the two groups. Taking β-blockers and diabetes may be the risk factors of death in maintenance hemodialysis patients with coronary artery disease, predialysis systolic blood pressure may be the protective factor.